JX-594: Interim Phase II data

Interim data from 7 evaluable patients in a Phase II trial showed that IV and intratumoral doses of JX-594 followed

Read the full 204 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE